18 and older
Non-Muscle Invasive Bladder Cancer, Bladder Cancer, BCG, ALT-803, Altor, Bacillus Calmette-Guerin, cancer, cytokine, IL-15, bladder
Your participation in the Study will include up to six (6) weekly doses of BCG plus ALT-803 or BCG alone. After the treatment is placed within your bladder, you will be asked to stay in the treatment center for up to four hours, so that we can carefully monitor your body’s functions and closely watch for potential side effects of the Study drug on your body.
Other standard medical and urology related examinations will be performed throughout the study. Follow up visits will also be required.
A more detailed schedule of events can be found below in the informed consent form.
Women and men 18 years and older with non-muscle invasive bladder cancer of the transitional cell carcinoma high-risk subtype.
A more detailed inclusion exclusion criteria can be found below in the informed consent form.